Showing 1671-1680 of 7242 results for "".
AAD & Week of Science, ADCETRIS CTCL Data, SILIQ Pricing
https://practicaldermatology.com/topics/skin-cancer-photoprotection/-dermwiretv-aad-week-of-science-adcetris-ctcl-data-siliq-pricing/18482/It's the Week of Science. The American Academy of Dermatology has joined a large group of other medical group in supporting the March for Science and its principles. Adults with hyperpigmentation tend to use sunscreen, but they are less likely to use other UV avoidance strategies, new research in JAThe Role of Microneedling in Practice
https://practicaldermatology.com/topics/aesthetics-cosmeceuticals/the-role-of-microneedling-in-practice/18627/Microneedling is gaining in popularity. Amy Forman Taub, MD discusses how she's using microneedling in combination with other treatments like PDT and RF to enhance efficacy and for faster results. She says the number one reason she uses microneedling is for scars. She also cautions on when not to usOffering Patients a Clean Slate with PicoWay
https://practicaldermatology.com/topics/aesthetics-cosmeceuticals/offering-patients-a-clean-slate-with-picoway/18656/Vic Narurkar, MD shares his work with Project New Start and helping high-risk youth with gang-related tattoos get a new start. Through the program, which Syneron-Candela helps to support, physicians volunteer to remove tattoos and help these patients turn their lives around through community serviceNewDerm LIVE: Update
https://practicaldermatology.com/topics/practice-management/newderm-live-update/18844/NewDerm LIVE is coming! September 18-20, 2015 at the W Hollywood, CA. Faculty member Neal Bhatia, MD talks to program co-chairs Peter Lio, MD about the goals of the meeting, the agenda, and exciting plans for the weekend. It's not too late to be part of this one-of-a-kind event. Register nowASDS: Dr. Munavalli on Combining Lasers and Topicals for Skin Cancer
https://practicaldermatology.com/conferences/asds-2024-annual-meeting/asds-dr-munavalli-combining-lasers-and-topicals-skin-cancer/29151/Girish Munavalli, MD, MHS, FAAD, discusses his lecture on lasers in combination with topical medications in the treatment of skin cancer at the 2024 American Society for Dermatologic Surgery Annual Meeting.Targeting Senescent Cells
https://practicaldermatology.com/series/c-suite-chats/targeting-senescent-cells/35960/Rubedo Life Science CEO Frederick Beddingfield III, MD, PhD, FAAD, FACMS, talks about the importance of addressing aging and senescence, and his company's investigational drug that targets pathological senescent cells and surrounding tissues that drive inflammaging and chronic degenerative diseasesPearls from CSF 2022
https://practicaldermatology.com/conferences/cosmetic-surgery-forum-2022/pearls-from-csf-2022/20163/It’s not just the attendees who learned at this year’s Cosmetic Surgery Forum. Meeting founder Joel Schlessinger, MD discusses some of the presentations that were most impactful to him. From presentations about the effectiveness of new technology to discussions about the usefulness of hyaluronidaseMaximizing Results: The Benefits of Biostimulators
https://practicaldermatology.com/conferences/asds-2022-annual-meeting/maximizing-results-the-benefits-of-biostimulators/20150/Patients often present with a desire for optimal results on a limited budget. Sabrina Fabi, MD shares how she effectively uses biostimulators in her practice. For low-volume, high-yield results, she recommends 1 vial every 8 months to a year. Alternating this with hyaluronic acid fillers, keeps everDERM2020 Content Recap: Linda Stein Gold, MD
https://practicaldermatology.com/conferences/dermatology-education-foundation-derm-2020/derm2020-content-recap-linda-stein-gold-md/19845/DERM2020 Faculty Linda Stein Gold, MD discusses what’s new in acne from her presentation during DERM2020.Dupixent, Juvéderm Vollure XC, Bavencio Approvals
https://practicaldermatology.com/topics/skin-cancer-photoprotection/dermwiretv-dupixent-juv-derm-vollure-xc-bavencio-approvals/18698/The FDA has approved Regeneron's injectable Dupixent (dupilumab) to treat adults with moderate-to-severe eczema. It will be marketed by Regeneron and Sanofi Genzyme in the US. Allergan's Juvéderm Vollure XC has received FDA approval based on a pivotal clinical trial in which 59 percent of subjects s